Lilly

1Q Revenues: $3.7 billion (+6%)

1Q Earnings: $834.8 million (+13%)

Comments: Revenue growth for the quarter was driven by Cymbalta and the company's other newer products. Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve, collectively grew 59%, to $802.4 million, and accounted for 22% of total sales, up from 14% in 1Q2005. Cymbalta generated $233.3 million in sales, up 118% and Cialis sales were $222.7 million, up 48%.

News from our sister sites